Background: Therapeutic applications of stem cells, especially mesenchymal stem cells, were once regarded as a promising therapy for mitigating acute cerebral infarction. Unfortunately, all the stem cell clinical trials have been futile. A new stroke therapeutic strategy of combining stem cells with nanotechnology has recently gained significant attention. The objective of this study was to evaluate the application of cerium oxide nanoparticle (nanoceria)-labeled human umbilical cord mesenchymal stem cells (HucMSCs) for stroke therapy. Methods: In our study, cerium oxide nanoparticles were precovered with hyaluronic acid before labeling HucMSCs and the synergistic effects from both HucMSCs and cerium oxide nanoparticles were analyzed in in vivo and in vitro experiments Results: The nanoceria-labeled HucMSCs combined advantages from both sides, including the capacity for inflammatory modulation of HucMSCs and the antioxidant effects of nanoceria. Compared with either HucMSCs or nanoceria individually, nanoceria-labeled HucMSCs exerted significantly enhanced capacities after gaining combined antioxidant and antiinflammatory effects. Conclusion: Our findings suggest a novel strategy with effective and well-tolerated applications of stem cells for acute cerebral infarction therapy after modification of cells with nanomaterials.
Introduction
Acute cerebral infarction (ACI) is a severe neurological disease with high disability worldwide. Currently, intravenous thrombolysis and endovascular intervention are clinically applicable treatments for ACI. However, both treatments have significant clinical limitations; they are only applicable either in the early stage of ischemic stroke or in a selective group of patients with stroke. Intravenous thrombolysis has a narrow therapeutic window, within 4.5 h after the onset of ACI. 1 Although endovascular intervention may be employed within 24 h after the onset of ischemic stroke in a strictly selected group of patients, 2,3 special devices and professional endovascular intervention specialist are required. Therefore, there is an urgent need of exploring other effective treatments for ACI.
Stem cell therapy after stroke has been regarded as a promising strategy to replace stroke-damaged tissue and to regain neurological function. 4 Neural stem cells (NSCs) are present in various parts of the central nervous system including the subventricular zone (SVZ) and subgranular zone (SGZ) of the dentate gyrus. 5 However, the regeneration capacities of NSCs are inadequate for reparation or replacement of damaged brain tissues after stroke. 6 For that reason, stem cell research in the stroke field has been focused on exogenous stem cell therapy. Mesenchymal stem cell (MSC) preparations are available from various donor tissues, and have low immunogenicity and minimal ethical concerns. 7, 8 Preclinical trials in animal models indicate that MSCs offer neuroprotection, angiogenesis and neurogenesis, probably via the modulation of the immune response. [9] [10] [11] [12] Clinical studies revealed the safety and feasibility in the MSC treatment of ischemic stroke. [13] [14] [15] [16] [17] However, meta-analysis indicates that the efficacy of the MSC treatment of ischemic stroke remains uncertain. 18, 19 Recent studies indicate that MSCs, which either overexpress growth factors or are preconditioned by drugs or combine with hypothermia, may enhance their beneficial effects. [20] [21] [22] [23] [24] [25] Indeed, these pretreatments of MSCs did increase the immunomodulatory features of MSC. However, these modified or preconditioned MSCs may still be inadequate for offering clinical benefits after ischemic stroke.
Cerium oxide nanoparticles (nanoceria) can reversibly bind to oxygen molecules, thus making a shift between Ce 3+ (reduced, electron donor) and Ce 4+ (oxidized, electron acceptor) on the surface of the particles. For that reason, nanoceria may scavenge intracellular reactive oxygen species (ROS). 26 Nanoceria may exert multiple effects under several disease conditions, including antioxidative stress, 27 anti-inflammation, 28 neuroprotection 29, 30 and radioprotection. 31 The objective of this study was to investigate whether nanoceria may further enhance MSC neuroprotective benefits in an animal stroke model.
Materials and methods

Synthesis of nanoceria
Nanoceria were synthesized by high temperature decomposition as reported previously. 32 Briefly, 0.434 g of Ce (NO 3 ) 3 ·6H 2 O, 0.802 g of oleylamine and 4.0 g of 1-octadecene were mixed and sufficiently dissolved at room temperature. During 30 min stirring at 80°C, the mixture solution was changed from dark brown to a clear brownish yellow solution. And then the resulting solution was heated for 2 h at 260°C. The remaining chemicals were removed using a washing solution of 1:1 of methanol and acetone by centrifugation. Highly purified nanoceria were obtained and dispersed in hexane or chloroform for further experiments.
Hyaluronic acid-coated nanoceria Nanoceria (5 mg, 1 mg/ml) were added to hyaluronic acid (25 mg, 5 mg/ml) in 30 ml of the solution with a mixture of hexane and ethanol. The reaction mixture was sonicated using a probe sonicator for 1 h at 40% amplitude and with cycles of 5 sec on and 2 sec off. Hexane and ethanol were removed by evaporation at 40°C. Purification of as-prepared hyaluronic acidcoated nanoceria (HA-CeO 2 ) were carried out using ultracentrifugation at 30,000 r/min for 30 min to remove the remaining hyaluronic acid. Finally, highly purified HA-CeO 2 pellets were dispersed in deionized water for further experiments. 2 The physicochemical properties of HA-CeO 2 were determined by different physicochemical techniques. The morphology, size, shape, and energy-dispersive X-ray spectroscopy (EDX) were characterized by transmission electron microscopy (TEM); the hydrodynamic diameters and surface charge were determined by dynamic light scattering and zeta potential, respectively; Ce 3+ /Ce 4+ patterns were determined by X-ray photoelectron spectroscopy (XPS); the concentrations of HA-CeO 2 were calculated by inductively coupled plasma mass spectrometry (ICP-MS).
Physicochemical characterization of HA-CeO
Cell culture
Human umbilical cord MSCs (HucMSCs) used in this study were kindly provided by Prof. Yufang Shi and his team (Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, China). HucMSCs were grown in low glucose Dulbecco's modified Eagle's medium (LG-DMEM) containing 10% fetal bovine serum, 1% penicillin and 1% streptomycin, and incubated in a humidified atmosphere (5% CO 2 ) at 37°C. To determine the anti-apoptotic activity of HA-CeO 2 , a Caspase-3/7 Green Flow Cytometry Assay Kit was used to detect the caspase-3/7 activity by flow cytometry (Attune ® NxT flow cytometer, Thermo Fisher).
In vivo experiments of a rat model
Animals
Specific pathogen-free Sprague-Dawley rats were housed in a 12 h light/dark cycle with access to food and water ad libitum. All animal procedures were conducted in accordance with guidance for the Care and Use of Laboratory Animals of Tongji University and were approved by the committee of experimental animals of Tongji University. Rats with 240-280 g body weight (7-8 weeks old) were used for this study.
Middle cerebral artery occlusion model
Rats were anesthetized intraperitoneally with pentobarbital sodium (40 mg/kg). The rats were subjected to middle cerebral artery occlusion (MCAO) according to the method described previously. 33, 34 Regional cerebral blood flow (CBF) was monitored by laser Doppler flowmetry of the Periflux system 5000 (Preimed, Sweden) with the use of a probe placed over the skull to confirm at least 70% reduction of the CBF. After 120 min of MCAO, the monofilament was removed to restore middle cerebral artery blood flow.
A total of 156 rats had established MCAO during this research. Among them, 32 rats were used for evaluation on the establishment of an optimal dose (see supplementary material). All other 124 rats were used for analyzing the effects of HA-CeO 2 -labeled HucMSCs as follows: 20 rats (5 rats in each group) were harvested 2 days after MCAO, 40 rats (10 rats in each group) were harvested 3 days after MCAO. The remaining 64 rats were used to record the weight, survival status and neurological examination till 7 days after MCAO.
Neurologic examination and group allocation
Neurologic impairment was evaluated 24 h and 7 days after cerebral reperfusion using a Bederson 4-point score and Garcia 18-point score. 35 In order to find the optimal dose of HucMSCs for transplantation, HucMSC doses of 1 × 10 6 , 2 × 10 6 and 4 × 10 6 were first evaluated after transplantation into MCAO rats. Then, neurologic scores and morphological changes of infarct areas were compared, which confirmed the HucMSC dose of 2 × 10 6 was optimal for transplantation into MCAO rats (see supplementary material). Rats were randomly divided into four groups after the first neurologic examination: (1) MCAO + 0.5 ml normal saline (NS) group as control; (2) MCAO + HucMSC group (each rat received 2 × 10 6 HucMSCs); (3) MCAO + HA-CeO 2 group (each rat received 0.5 mg/kg HA-CeO 2 according the previous report 30 ) and MCAO + HA-CeO 2 -labeled HucMSC group (2 × 10 6 HucMSClabeled 0.5 mg/kg HA-CeO 2 ). HucMSCs and HA-CeO 2 were suspended in 0.5 ml NS and transplanted via the caudal vein into rats. Each rat of the control group received 0.5 ml NS. The body weights and death of animals were recorded daily.
Measurement of infarct area
At Day 7 after MCAO, rats were anesthetized with an overdose of pentobarbital sodium and the brains were rapidly removed and frozen at −20ºC for 15 min. Then the brains were sliced into seven serial 2-mm coronal sections and incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma, USA) at 37ºC for 10 min. The extent of the infarction area and normal brain area were outlined manually and calculated using ImageJ software (National Institutes of Health, version journals.sagepub.com/home/tan 5
1.44). The infarction volumes were expressed as the total infarct area multiplied by the thickness of brain sections. To evaluate the effect of correcting acute brain edema, the lesion volume was determined as: the corrected infarct area = [infarct − (ipsilateral hemisphere − contralateral hemisphere)]/contralateral hemisphere × 100, as described previously. [36] [37] [38] Real-time quantitative polymerase chain reaction Total RNA was isolated from the infarct and surrounding tissues of each individual rat (n = 5) at Days 3 and 7 after MCAO by using TRIzol Reagent (Invitrogen, USA). Real-time quantitative polymerase chain reaction (PCR) was performed using the Applied Biosystems real-time Prism 7900 HT Sequence Detection System (ABI, USA). The sequences of primers are listed in Table 1 .
ROS measurement
Rat brain tissues from each group at Days 2, 3 and 7 (n = 5) after MCAO were harvested and all procedures were done as the instructions in the rat ROS enzyme-linked immunosorbent (ELISA) kit (R&D). Details are available from the supplementary data.
Cytokine measurements Rat brain tissues homogenates from each group at Days 2, 3 and 7 (n = 5) after MCAO were analyzed and assayed for cytokines using multiplexed beadbased immunoassay kit for rats including interleukin (IL)-1β, IL-4, IL-6, IL-10, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, vascular endothelial growth factor (VEGF) and regulated upon activation normal T-cell expressed and secreted (RANTES) combined with a reagent kit (Bio-Rad, #171-304070). All procedures were done as per manual instructions and details are available from the supplementary data.
Apoptosis
Apoptotic cells of rat brain tissues from each group at Days 3 (n = 5) after MCAO were analyzed by a TUNEL kit (Roche, Switzerland). Brain tissues embedded in paraffin were cut in 4-μm thick slices. Labeled apoptotic cells were identified by treating the sections with the peroxidased chromogenic substrate 3,3′-diaminobenzidine (DAB) as recommended in the kit. Overall, five random selective observed fields of each slice were photographed under light microscopy with magnification ×200 and the apoptotic cells were BDNF, brain-derived neurotrophic factor; GAPDH, glyceraldehyde phosphate dehydrogenase; GDNF, glial-derived neurotrophic factor; iNOS, inducible nitric oxide synthase; NF-κB, nuclear factor κB; NGF, nerve growth factor; Nrf2, nuclear factor-erythroid-2-related factor 2; NT-3, neurotrophin 3; Prdx6, peroxiredoxin 6; VEGF, vascular endothelial growth factor.
counted with Image-Pro Plus software (Media Cybernetics, version 6.0). The percentage of apoptotic cells to normal cells were summed then averaged in each group.
Statistical analysis
All statistical analyses were performed using GraphPad Prism software (GraphPad software, version 5.0). Presented data are reported as means ± standard error of the mean. A p value <0.05 was considered significant. known that the nanoceria with a higher Ce 3+ to Ce 4+ ratio were more effective against the diseases associated with oxidative stress or inflammation, owing to their higher oxygen vacancy and superoxide dismutase (SOD) mimetic activity.
Results
Synthesis and characterization of the HA-CeO
Biocompatibilities were proved after HucMSCs labeling with HA-CeO 2
Results of the MTT assay proved that there was no significant difference for the viabilities of HucMSCs at 24 h after labeling with HA-CeO 2 at a series of concentrations from 0 μM to 300 μM [ Figure 2(a) ]. Under the same situations, the expression levels of CXCR4 protein in HucMSCs with HA-CeO 2 at several concentrations (25, 50, and 150 μM) indicated that the CXCR4 expression levels had no significant difference, suggesting that HA-CeO 2 labeling did not influence CXCR4 protein expression in HucMSCs [ Figure  2 (b, c)]. Furthermore, our results also showed that HA-CeO 2 had no effect on HucMSCs migration [ Figure 2(d) ]. Finally, results of phenotypic analyses on the surface markers indicated that positive staining for CD29, CD44, CD90 and CD105 and negative staining for CD45 and CD34 were achieved on both nonlabeled HucMSC controls and labeled HucMSC at 24 h Figure 5 (e)].
Next, the Bederson neurologic score and Garcia scores were recorded for the evaluation of therapeutic effects. Results indicated that there was no significant difference between the Bederson neurologic score among the three treatment groups and the control group at Day 1 and Day 7 after MCAO. There was also no significant difference in Garcia scores among all four groups at Day 1. However, at Day 7 after MCAO, the Garcia neurologic score was significantly higher in the HA-CeO 2 -labeled HucMSC group than the control group (p < 0.05), which was 12.3 ± 1.0 in the HA-CeO 2 -labeled HucMSC group, 11.6 ± 1.2 in the HucMSC group and 12 ± 1.8 in the HA-CeO 2 group, when compared with 11.3 ± 1.0 in the control group [ Figure 5 In summary, our results proved that HA-CeO 2 -labeled HucMSCs significantly promoted the weight and neurological recovery and exhibited positive effects for rats after MCAO.
HA-CeO 2 -labeled HucMSCs decreased infarct volume after MCAO
After TTC staining, the infarct area in the brain was white in color, while the normal tissue area was red in color [ Figure 5(a) ]. Remarkably, for infarction volume percentages, significant differences existed between each of three experimental groups and control group. The detailed results were summarized between the HA-CeO 2 -labeled HucMSC group and control (20.5 ± 7% versus 40.1 ± 3%, p < 0.01, n = 8), between the HucMSC group and control (25.6 ± 5% versus 40.1 ± 3%, p < 0.05, n = 8) and between the HA-CeO 2 group and the control (25.5 ± 9% versus 40.1 ± 3%, p < 0.05, n = 8), respectively. The level of the infarction volume percentage was little smaller in the HA-CeO 2 -labeled HucMSC group than the HA-CeO 2 group or HucMSC group [ Figure 5(a, b) ]. However, the overall differences among the three experimental groups were not significant. Together, these results of the TTC assay proved that HA-CeO 2 -labeled HucMSCs helped to decrease the cerebral infarction volume effectively.
Enhanced antioxidative capacity of HA-CeO 2 -labeled HucMSCs
To evaluate the effect of antioxidative stress of HA-CeO 2 -labeled HucMSCs in transplanted MCAO rats, an ELISA was used to detect the levels of ROS expression in rat brain samples harvested at Days 2, 3 and 7 after MCAO. ROS expressions in the HA-CeO 2 -labeled HucMSC group were significantly reduced at Day 7 compared with the control group [12.11 ± 0.83 IU/ mg versus 27.64 ± 4.29 IU/mg, p < 0.05; Figure  6 (i)]. Next, a real-time PCR assay was used to evaluate the expression levels of several genes relative to oxidative stress in the harvested rat brain tissues after MCAO, including inducible nitric oxide synthase (iNOS), nuclear factorerythroid-2-related factor 2 (Nrf2) and peroxiredoxin 6 (Prdx6 HA, hyaluronic acid; CeO2, nanoceria; HucMSCs, Human umbilical cord mesenchymal stem cells; mRNA, MCAO, middle cerebral artery occlusion; PCR, Polymerase Chain Reaction; iNOS, inducible nitric oxide synthase; GDNF,glial-derived neurotrophic factor; Nrf2, nuclear factor-erythroid-2-related factor 2; VEGF, vascular endothelial growth factor; ELISA, Enzyme-linked immunosorbent assay; IFN-γ, interferon-γ; TNF-α, umor necrosis factor -α; IL-6, Interleukin-6; RANTES, regulated upon activation normal T cell expressed and secreted; ROS, Reactive Oxygen Species. Results of our analyses to study the mechanism of the effects of HA-CeO 2 -labeled HucMSCs for ACI therapy implied that antioxidant properties of HA-CeO 2 -labeled HucMSCs was obtained through downregulation of iNOS and upregulation of Nrf2 at the levels of their gene expression. The expression of iNOS was upregulated under ischemic injury, which resulted in an increase of nitric oxide (NO) production. These findings could be explained by NO being a key factor acting during oxidative stress, which increases the formation of peroxynitrite. 40, 41 Furthermore, activated Nrf2 could mediate the induced expression of an array of enzymes and signaling proteins to regulate antioxidant defense because Nrf2 has already been known previously as a key regulator of cellular resistance to oxidants. 42 Our results also indicated that the immunomodulatory effect of HA-CeO 2 -labeled HucMSC treatment was higher than that of either individual HucMSC treatment or individual HA-CeO 2 treatment, which included the effects of negatively influencing the expression of inflammatory factors including TNF-α, IFN-γ, IL-6 and RANTES. Remarkably, both TNF-α and IFN-γ are known as the important cytokines for inducing neuronal cell apoptosis. 43, 44 Therefore, the decreased expression of both TNF-α and IFN-γ after the treatment of transplantation of HA-CeO 2 -labeled HucMSCs could be beneficial to the rats after MCAO. IL-6 is known as another important cytokine involving in cerebral ischemia. 45 Previously, the elevated IL-6 level in serum was found in acute stroke patients, and was regarded to associate with infarct volume and prognosis. 45 But the results from some recent studies suggested that IL-6 might act as a neuroprotective cytokine in stroke. 46 The decreased expression of IL-6 found in the HA-CeO 2 -labeled HucMSC-treated group during our study seemed to correlate more with the results in the improved neurological scores and the recovered animal body weights. However, these results were also not consistent with the previous realization of IL-6 acting as a neuronal protective agent. Therefore, the exact mechanism of decreased expression of IL-6 will be further investigated in our future study. RANTES is known as a chemokine that promotes the migration of leukocytes into damaged tissue and mediates cerebral inflammation and injury. 47 Here, our results of the downregulation of RANTES could be well explained by its consistence with the resultant decrease in injury after cerebral ischemia. Our results of the neurotropic effects of HA-CeO 2 -labeled HucMSCs were consistent with previously published findings. 48 Nicole and colleagues indicated that the neuroprotection of GDNF involved in the reduction of N-methyl-D-aspartic acid (NMDA)-induced calcium influx. In addition, it was also possible that the persistently elevated GDNF and VEGF could increase neurogenesis and angiogenesis. 49 The details of how HA-CeO 2 -labeled HucMSCs performed the enhanced effects of neuroprotection are expected to be elucidated in our subsequent study.
Gliga and colleagues 50 reported that nanoceria could inhibit neuronal differentiation in vitro because nanoceria interfered with the expression of β3-tubulin and Glial fibrillary acidic protein (GFAP), and this inhibition effect partly related to the antioxidant properties of nanoceria. In addition, because endogenous neurogenesis is one of the important mechanisms after stem cell transplantation to the rat ischemic stroke model, the downregulation of genes relative to neurogenesis may influence the long-term recovery of stroke animals. The different effects of nanoceria may also relate to the different doses, the different sizes, and the differences in shape of particles and ratios of Ce 3 + to Ce 4 +. Therefore, the effects of HA-CeO 2 or HA-CeO 2 -labeled HucMSCs on neurogenesis will be further investigated in our future study.
Conclusion
In conclusion, we generated nanoceria that have considerable biocompatibility and promising scavenging activity of intracellular ROS. The nanoceria-labeled HucMSCs have the combined advantages from two original units (individual HucMSC and nanoceria) after the modification of cell labeling, which are the capacity of inflammation responses for HucMSCs and antioxidant effects for nanoceria. Moreover, we have proven that nanoceria-labeled HucMSCs have significantly enhanced antioxidant, inflammatory modulation, anti-apoptosis and neurotrophy properties when compared with applying HucMSCs and nanoceria before the cell labeling modification. Therefore, our study provides a new insight into the interface between nanotechnology and medicine for clinical applications. Our findings also suggest that transplantation of nanoceria-labeled HucMSCs could be used as a novel strategy for the effective and well-tolerated treatment of ACI in the future.
